Keyphrases
Co-infected Patients
59%
Ribavirin
45%
Hepatitis C Virus
44%
Spain
32%
HIV-HCV
31%
Sustained Virological Response
26%
Pegylated Interferon
23%
Anti-hepatitis C Virus Antibody
16%
Genotype
13%
Hepatitis C Virus Infection
13%
Tolerability
13%
SVR12
13%
Genotype 1
12%
Direct-acting Antivirals
12%
Hepatitis C Virus RNA
12%
Interferon-α (IFN-α)
11%
Sustained Viral Response
11%
Anti-hepatitis C Virus
10%
Ribavirin-induced Anemia
10%
ITPA Gene
10%
Faldaprevir
10%
Giant Cell (temporal) Arteritis
10%
Effective Model
10%
Emergency Service
10%
Churg-Strauss Syndrome
10%
Hepatic Decompensation
10%
Nevirapine
10%
Antineutrophil Cytoplasmic Antibody
10%
Neuropsychiatric Symptoms
10%
Sofosbuvir
10%
Combination Therapy
10%
Hepatitis C Virus Genotypes
10%
Gene Polymorphism
10%
Antiviral Drugs
10%
Care Planning
10%
Liver Stiffness
10%
Telaprevir
10%
Predictive Factors
10%
Janus Kinase Inhibitors
10%
Rheumatoid Arthritis
10%
Inhibitor Study
10%
Adverse Reactions
10%
Cell Count
10%
Titer
10%
Hepatitis C Coinfection
10%
Patient Characteristics
10%
CD4+
10%
Prevalence Characteristics
10%
People Living with HIV (PLHIV)
10%
Epidemiological Trends
10%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Hepatitis C Virus
51%
Ribavirin
49%
Mixed Infection
32%
Peginterferon
23%
Interferon
21%
Liver Cirrhosis
20%
Prevalence
19%
Tolerability
13%
Viral Clearance
13%
Faldaprevir
10%
Anemia
10%
Decompensated Liver Cirrhosis
10%
Telaprevir
10%
Intervention Study
10%
Hepatitis C Virus Genotype 1
10%
Combination Therapy
10%
Hospital Pharmacy
10%
Antivirus Agent
10%
Nevirapine
10%
Janus Kinase Inhibitor
10%
Rheumatoid Arthritis
10%
Adverse Event
10%
Inflammatory Arthritis
10%
Elimination
10%
Virus Hepatitis
10%
Hepatitis C
10%
Side Effect
9%
Virus RNA
7%
Infection
6%
Virus Antibody
5%
Efavirenz
5%
Sofosbuvir
5%
Ledipasvir Plus Sofosbuvir
5%
Virotherapy
5%
Immunology and Microbiology
Human Immunodeficiency Virus
93%
Hepatitis C Virus
54%
Ribavirin
42%
Prevalence
27%
Pegylated Interferon
23%
Coinfection
22%
Interferon Type I
22%
Virus Antibody
13%
Hepatitis E Virus
10%
Titer
10%
CD4 Lymphocyte Count
10%
Hepatitis C Virus Genotype 1
10%
DNA Polymorphism
10%
Hepatitis E
10%
Churg-Strauss Syndrome
10%
Gene Expression
10%
Foreign-Body Giant Cell
10%
Temporal Arteritis
10%
Peripheral Blood Mononuclear Cell
10%
Hepatitis Virus
10%
Viral Clearance
10%
Neutrophil Cytoplasmic Antibody
10%
Telaprevir
10%
Virus
10%
Sustained Viral Response
8%
Hepatitis C
7%
Virotherapy
5%
